Axxcess Wealth Management LLC Sells 3,491 Shares of UiPath Inc. (NYSE:PATH)

Axxcess Wealth Management LLC decreased its position in UiPath Inc. (NYSE:PATH) by 12.0% during the fourth quarter, Holdings Channel reports. The fund owned 25,630 shares of the healthcare company’s stock after selling 3,491 shares during the period. Axxcess Wealth Management LLC’s holdings in UiPath were worth $637,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of PATH. 180 Wealth Advisors LLC grew its holdings in UiPath by 0.3% during the fourth quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock valued at $4,497,000 after purchasing an additional 492 shares during the period. Bleakley Financial Group LLC grew its stake in shares of UiPath by 4.9% during the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after acquiring an additional 598 shares during the period. Simplicity Solutions LLC increased its holdings in UiPath by 4.9% in the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after acquiring an additional 598 shares in the last quarter. Arizona State Retirement System raised its stake in UiPath by 0.8% during the 3rd quarter. Arizona State Retirement System now owns 97,951 shares of the healthcare company’s stock worth $1,676,000 after acquiring an additional 733 shares during the period. Finally, Treasurer of the State of North Carolina lifted its holdings in UiPath by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 164,988 shares of the healthcare company’s stock valued at $2,823,000 after purchasing an additional 840 shares in the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at UiPath

In related news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at approximately $14,312,104.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 31.03% of the company’s stock.

UiPath Trading Up 0.8 %

PATH opened at $20.01 on Wednesday. The stock has a 50-day moving average of $21.67 and a 200 day moving average of $21.75. UiPath Inc. has a 12 month low of $12.89 and a 12 month high of $27.87. The firm has a market cap of $11.39 billion, a P/E ratio of -117.71 and a beta of 1.01.

UiPath (NYSE:PATH) last announced its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The firm had revenue of $405.25 million during the quarter, compared to analysts’ expectations of $383.32 million. On average, research analysts forecast that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on PATH shares. Mizuho raised their price objective on shares of UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. Evercore ISI raised their price target on UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a report on Thursday, March 14th. Canaccord Genuity Group upped their price objective on UiPath from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Wells Fargo & Company increased their target price on UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 14th. Finally, Morgan Stanley upped their price target on UiPath from $17.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 14th. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.41.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.